Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| MSGY | Masonglory | $2.05 | -$4.21 | -67.25% | 12.5M | $89M | $0.70$22.20 |
| VTIX | Virtuix | $10.67 | -$13.72 | -56.25% | 1.3M | $752M | $10.44$92.74 |
| AGPU | Axe Compute | $3.37 | -$1.67 | -33.13% | 279K | $17M | $2.86$39.00 |
| FEAM | 5e Advanced Materials | $2.26 | -$0.92 | -28.93% | 1.1M | $71M | $2.16$10.74 |
| XHLD | Ten | $2.55 | -$0.97 | -27.56% | 2.4M | $10M | $1.05$128.10 |
| GITS | Global Interactive Technologies | $3.18 | -$1.00 | -23.86% | 1.8M | $15M | $0.66$7.09 |
| GRI | Gri Bio | $4.11 | -$1.21 | -22.74% | 12.7M | $2.9M | $3.87$333.20 |
| HIND | Vyome | $2.54 | -$0.72 | -22.09% | 1.1M | $18M | $2.52$394.00 |
| ENVB | Enveric Biosciences | $3.49 | -$0.95 | -21.31% | 255K | $4.5M | $3.40$57.96 |
| NETG | Themes ETF Trust - Leverage Shares 2x Long Net Daily ETF | $10.66 | -$2.78 | -20.71% | 463.9K | - | $9.23$15.11 |
Related Articles
Featured Article
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Adam Spatacco|Aug 9, 2024
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
Alex Carchidi|Jul 20, 2024
At least one of the pair has a credible shot at finding a home in the market.
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
Alex Carchidi|Jul 10, 2024
Both competitors have promising lead programs, and enough cash, too.
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
Alex Carchidi|Jun 30, 2024
While their share prices have traveled different paths recently, the similarity between the two companies is striking.
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Alex Carchidi|Jun 29, 2024
The market for weight loss medicines keeps getting hotter and hotter.
This Ultra Cheap Lending Stock Is Up 21% in June. Is It a Buy?
Courtney Carlsen|Jun 20, 2023
This student lender could benefit from the resumption of student loan repayments.
Does an FDA Fast Track Designation Make Regenxbio Stock a Buy Now?
James Halley|Apr 15, 2023
The company focuses on using its technology for gene-editing therapies.
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.
Keith Speights|Mar 22, 2023
It's not the end of the story for this once high-flying biotech stock.
My 3 Top Biotech Stock Picks for 2023
George Budwell, PhD|Nov 22, 2022
Biotech stocks are set to shine in 2023.
3 Small-Cap Medical Stocks With Big Momentum
James Halley|Apr 27, 2022
Now is a good time to take a closer look at these stocks.
